Silexion Therapeutics Corp — Form SCHEDULE 13D/A
Filed September 28, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 12/100
What the filing says
Moringa Sponsor, LP filed an amended Schedule 13D/A on 2026-09-28 regarding beneficial ownership in Silexion Therapeutics Corp (a $4.2M-asset biotech company). The filing document itself contains no substantive disclosure of counterparties, dollar amounts, share counts, beneficial ownership percentages, or what specifically changed from the prior filing—only metadata and header information are visible in this submission.
Why this rating
No material facts disclosed; appears to be administrative/procedural amendment. Cannot assess ownership change or deal terms without actual filing content details.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.